AQXP - Neoleukin Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.6800
+0.2100 (+6.05%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.4700
Open3.5000
Bid0.0000 x 3000
Ask0.0000 x 900
Day's Range3.4614 - 3.8300
52 Week Range2.0000 - 4.2300
Volume513,928
Avg. Volume122,774
Market Cap103.508M
Beta (3Y Monthly)0.92
PE Ratio (TTM)N/A
EPS (TTM)-0.9380
Earnings DateMar 14, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction

    Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals, Inc. (AQXP). Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol “NLTX” beginning on Monday, August 12, 2019, on the Nasdaq Global Market. Following the close of the transaction, and after giving effect to conversion of preferred shares into common subject to a stockholder vote, there are expected to be 38.3 million total shares of common stock outstanding.  The corporate headquarters are now located in Seattle, Washington at Neoleukin’s existing facility.

  • UW spinout Neoleukin Therapeutics goes public in acquisition
    American City Business Journals

    UW spinout Neoleukin Therapeutics goes public in acquisition

    The public company will change its name to Neoleukin Therapeutics and will be based in Seattle when the deal closes.

  • GlobeNewswire

    Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

    Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (AQXP), today announced that Jonathan G. Drachman, M.D., CEO, of Neoleukin, will present a corporate overview at the Canaccord Genuity 39th Annual Growth Conference in New York, NY on Thursday, August 8th, 2019 at 3:00 p.m. Eastern. In connection with the merger, Aquinox will be renamed as Neoleukin Therapeutics, Inc. and is expected to trade on the Nasdaq under the new ticker symbol NLTX at the time of closing, on or about August 8th, 2019, subject to customary legal and regulatory clearances and procedures. Neoleukin is a biopharmaceutical company creating next generation immunotherapies using de novo protein design technology.  Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

  • GlobeNewswire

    Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement

    Aquinox Pharmaceuticals, Inc. (“Aquinox”) (AQXP) and Neoleukin Therapeutics, Inc. (“Neoleukin”), a privately held biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that the two companies entered into a definitive merger agreement under which Aquinox agreed to the acquisition of Neoleukin, which is expected to close on or about August 8th, 2019. Pursuant to the merger agreement, Aquinox will acquire all of the outstanding capital stock of Neoleukin in exchange for a combination of common and preferred shares.  In connection with the merger, Aquinox will be renamed as Neoleukin Therapeutics, Inc., and is expected to trade on the Nasdaq Global Market under the new ticker symbol “NLTX”, concurrent with closing.

  • Imagine Owning Aquinox Pharmaceuticals (NASDAQ:AQXP) While The Price Tanked 68%
    Simply Wall St.

    Imagine Owning Aquinox Pharmaceuticals (NASDAQ:AQXP) While The Price Tanked 68%

    Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) shareholders should be happy to see the share price up 10% in the last...

  • What Kind Of Shareholder Appears On The Aquinox Pharmaceuticals, Inc.'s (NASDAQ:AQXP) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Aquinox Pharmaceuticals, Inc.'s (NASDAQ:AQXP) Shareholder Register?

    The big shareholder groups in Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies...

  • Associated Press

    Aquinox: 3Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 64 cents. The company's shares closed at $2.48. A year ago, they were trading at $11.40. _____ This story was generated ...

  • GlobeNewswire

    Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results

    VANCOUVER, British Columbia, Nov. 07, 2018 -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates.

  • GlobeNewswire

    Consolidated Research: 2018 Summary Expectations for Aquinox Pharmaceuticals, Xilinx, West Pharmaceutical Services, nVent Electric, World Wrestling Entertainment, and HD Supply — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 01, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.